Introduction Pneumocystis jirovecii pneumonia (PJP) is one of the most common opportunistic infections in people with HIV (PWH) and advanced immunodeficiency [1], leading to severe hypoxemia due to diffusion capacity impairment [2]. The introduction of combination antiretroviral therapy and improved PJP treatment strategies have led to a significant decline in mortality from PJP, but it is unclear whether pulmonary function abnormalities completely resolve in this population [3,4].
